• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy

Nov. 22, 2011
By Marie Powers
Thanksgiving came early for Pharmasset Inc. with the news that Gilead Sciences Inc. will gobble it up in a deal valued at $11 billion.
Read More

Will Deal Pave the Way for Other Moves in HCV Space?

Nov. 22, 2011
By Marie Powers
As analysts and investors digested the implications of the colossal combination of Gilead Sciences Inc. and Pharmasset Inc. on the hepatitis C virus (HCV) market, some began to speculate on the logical next question: What comes next?
Read More

Agios Scores $78M to Advance Its Cancer Metabolism Work

Nov. 18, 2011
By Marie Powers
Agios Pharmaceuticals bagged $78 million in an oversubscribed Series C, signaling that the financing gate – if not floodgate – remains open for emerging biotechs.
Read More

Idenix Prices $70.3M Offering on Basis of Stock's Strength

Nov. 17, 2011
By Marie Powers
Idenix Pharmaceuticals Inc. took advantage of the tailwind in its stock, which on Tuesday hit a 52-week high of $7.38, by pricing a public offering disclosed one day earlier.
Read More

Bellicum Pharma Goes To War Using its Cell Therapy

Nov. 15, 2011
By Marie Powers
Bellicum Pharmaceuticals Inc., whose name loosely translates from Latin as "call to war," is developing technology that seeks out and eliminates the donor T cells that cause graft-vs.-host disease (GVHD), an often-fatal complication of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia.
Read More

Signum, GSK Agree to Probe Phosphatase 2A as AD Target

Nov. 11, 2011
By Marie Powers
Privately held biotech Signum Biosciences Inc. signaled its intention to play in a bigger sandbox on Wednesday by signing an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to advance Signum's phosphatase screening technology, which targets the phosphoprotein phosphatase 2A (PP2A) as a key mechanism in Alzheimer's disease (AD).
Read More

Mpex Successor Rempex Snags up to $67.5M in Series B

Nov. 10, 2011
By Marie Powers
Rempex Pharmaceuticals Inc., formed in June to acquire the human, financial and clinical assets unrelated to Aeroquin from Mpex Pharmaceuticals Inc., has attracted a commitment of up to $67.5 million to advance the development of treatments for resistant Gram-negative infections.
Read More

Another IPO! TVAX Seeks $40M To Fund Cancer Immunotherapy

Nov. 9, 2011
By Marie Powers
Cancer immunotherapy firm TVAX Biomedical Inc. became the latest biotech to line up this year for an initial public offering, filing an S-1 on Monday and seeking to raise $40 million.
Read More

NPS Pharmaceuticals Seeks Bounce from Natpara Phase III

Nov. 8, 2011
By Marie Powers
One week after shares of NPS Pharmaceuticals Inc. were drubbed over safety concerns about the GLP-2 analogue Gattex (teduglutide) in short bowel syndrome, the company sought a ray of sunshine with positive top-line results from its pivotal Phase III REPLACE study of Natpara (NPSP558), a bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients. (See BioWorld Today, Nov. 1, 2011.)In an intent-to-treat analysis, NPS reported that 53 percent (48/90) of Natpara-treated patients achieved the primary endpoint vs.
Read More

Dendreon Shares Sink on Another Provenge Miss

Nov. 4, 2011
By Marie Powers
Despite a growing revenue stream – $64.3 million in the third quarter compared to $20.2 million in the same period a year earlier and nearly 30 percent more than the second quarter – Dendreon Corp.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe